-
Sanofi, Regeneron Report Positive Phase 3 Results For Asthma Drug Dupixent's Use In Children
Tuesday, October 13, 2020 - 5:46am | 418Read More...Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) disclosed that their asthma drug Dupixent (dupilumab) met its primary and all key secondary endpoints in randomized Phase 3 clinical trials demonstrating improved lung functions in children aged between six to 11 years. Data...
-
Amid Few Catalysts, Jefferies Downgrades AstraZeneca
Tuesday, March 15, 2016 - 8:07am | 277Read More...Jefferies’ Jeffrey Holford downgraded the rating on AstraZeneca plc (ADR) (NYSE: AZN) from Buy to Hold, while lowering the price target from 4,900p to 4,350p. Limited Catalysts In 2016 Holford believes that there are limited catalysts for the stock in 2016 that could drive multiple...
